Comparison of Conventional Gadoxetate Disodium-Enhanced MRI Features and Radiomics Signatures With Machine Learning for Diagnosing Microvascular Invasion
Overview
Affiliations
This study aimed to determine the best model for predicting microvascular invasion (MVI) of hepatocellular carcinoma (HCC) using conventional gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (gadoxetate disodium)-enhanced MRI features and radiomics signatures with machine learning. This retrospective study included 269 patients with a postoperative pathologic diagnosis of HCC. Gadoxetate disodium-enhanced MRI features were assessed, including T1 relaxation time, tumor margin, tumor size, peritumoral enhancement, peritumoral hypointensity, and ADC. Radiomics models were constructed and validated by machine learning. The least absolute shrinkage and selection operator (LASSO) was used for feature selection, and radiomics-based LASSO models were constructed with six classifiers. Predictive capability was assessed using the ROC AUC. Histologic examination confirmed MVI in 111 (41.3%) of the 269 patients. ADC value, nonsmooth tumor margin, and 20-minute T1 relaxation time showed diagnostic accuracy with AUC values of 0.850, 0.847, and 0.846, respectively ( < .05 for all). A total of 1395 quantitative imaging features were extracted. In the hepatobiliary phase (HBP) model, the support vector machine (SVM), extreme gradient boosting (XGBoost), and logistic regression (LR) classifiers showed greater diagnostic efficiency for predicting MVI, with AUCs of 0.942, 0.938, and 0.936, respectively ( < .05 for all). ADC value, nonsmooth tumor margin, and 20-minute T1 relaxation time show high diagnostic accuracy for predicting MVI. Radiomics signatures with machine learning can further improve the ability to predict MVI and are best modeled during HBP. The SVM, XGBoost, and LR classifiers may serve as potential biomarkers to evaluate MVI.
Zhang W, Guo Q, Zhu Y, Wang M, Zhang T, Cheng G Cancer Imaging. 2024; 24(1):142.
PMID: 39438929 PMC: 11520182. DOI: 10.1186/s40644-024-00790-9.
Shen Q, Xiang C, Huang K, Xu F, Zhao F, Han Y Am J Cancer Res. 2024; 14(9):4445-4458.
PMID: 39417193 PMC: 11477817. DOI: 10.62347/AXQW1100.
Leveraging radiomics and AI for precision diagnosis and prognostication of liver malignancies.
Haghshomar M, Rodrigues D, Kalyan A, Velichko Y, Borhani A Front Oncol. 2024; 14:1362737.
PMID: 38779098 PMC: 11109422. DOI: 10.3389/fonc.2024.1362737.
Brancato V, Cerrone M, Garbino N, Salvatore M, Cavaliere C World J Gastroenterol. 2024; 30(4):381-417.
PMID: 38313230 PMC: 10835534. DOI: 10.3748/wjg.v30.i4.381.
Cannella R, Santinha J, Beaufrere A, Ronot M, Sartoris R, Cauchy F Eur Radiol. 2023; 33(11):7618-7628.
PMID: 37338558 DOI: 10.1007/s00330-023-09852-1.